Address of Corresponding Author

Intervirology 2006;49:18-22 (DOI: 10.1159/000087258)

  Key Words

• Epidemiology
• Genotypes
• Hepatitis C virus
• Korea
• Transfusion

  Abstract

Mortality due to liver cancer in Korea ranks as one of the highest in the world. Both hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are high-risk factors for liver cancer. Although HBV is by far the more important risk factor for the development of hepatocellular carcinoma (HCC) in Korea, HCV infection is more closely associated with HCC in elderly patients. Therefore, the evaluation of risk factors for HCV infection, including blood transfusion, is important. This study reviews the literature on HCV prevalence and risk factors among the general population, as well as the distribution of HCV genotypes in Korea. An overall estimate of the prevalence of anti-HCV among Koreans older than 40 years was 1.29% (95% confidence interval 1.12-1.48) during 1995-2000. Blood transfusion was the strongest risk factor for transmission of HCV infection. Risk factors for HCV infection in Korea other than blood transfusion and history of acupuncture have not been proven. The most prevalent HCV genotype is 1b followed by 2a. Even though the prevalence of anti-HCV in Korea has been reduced and the risk of HCV transmission through blood transfusion has markedly decreased, public-health programs to prevent de novo infections should be developed. Moreover, most people infected with HCV in Korea are older than 40 years, and therefore, the surveillance of adults (40 years) for HCV infection will be helpful in early detection of HCC developing in them.

Copyright © 2006 S. Karger AG, Basel

  References

1.

Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, Ahn YO, Shigemastu T: Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: A case-control study in Pusan, Korea. Int J Epidemiol 1996;25:933-940.

2.

Lee HS, Han CJ, Kim CY: Predominant etiologic association of hepatitis C virus with hepatocellular carcinoma compared with hepatitis B virus in elderly patients in a hepatitis B-endemic area. Cancer 1993;72:2564-2567.

3.

Kim O, Kim SS, Park MS, Suh SD, Lee MW, Kim KS, Yoon JD, Lee JS: Seroprevalence of sexually transmitted viruses in Korean populations including HIV-seropositive individuals. Int J STD AIDS 2003;14:46-49.

4.

Kim YS, Pai CH, Chi HS, Kim DW, Min YI, Ahn YO: Prevalence of hepatitis C virus antibody among Korean adults. J Korean Med Sci 1992;7:333-336.

5.

Yoon DK, Cho KW, Hong MH, Kwon SY, Byun KS, Lee CH: Prevalence of antibody to hepatitis C virus in Korean adults (in Korean). Korean J Infect Dis 1994;26:237-247.

6.

Kim WS, Dam DO, Shin HR, Jung KY, Kim JY: Epidemiologic study of hepatitis B and C among adults in Pusan (in Korean). J Pusan Med Assoc 1995;31:18-28.

7.

Shin HR, Kim JY, Jung KY, Kim WS, Hong YS, Kim BK, Kim SR, Lee BO, Park TS, Lee YH, Ok ID, Ryan MK, Taniguchi M, Kim MM, Kim KI: Prevalence of hepatitis B and C virus infection among adults in Korea. Hepatol Res 1997;7:213-225.

8.

Jeong TH, Jeon TH: PCR prevalence and risk factors of hepatitis C virus infection in the adult population of Ulsan (in Korean). J Korean Acad Fam Med 1998;19:364-373.

9.

Seo WT, Lee SS: A study on positive rate of HBsAg, HBsAb and anti-HCV in Korean adults (in Korean). Korean J Blood Transfus 1998;9:259-272.

10.

Na HY, Park MH, Park KS, Sohn YH, Joo YE, Kim SJ: Geographic characteristics of positive anti-HCV and hepatitis B surface antigen in Kwangju and Chonnam Province: Survey data of 6,790 health screenees (in Korean). Korean J Gastroenterol 2001;38:177-184.

11.

Park KS, Lee YS, Lee SG, Hwang JY, Chung WJ, Cho KB, Hwang JS, Ahn SH, Park SK: A study on markers of viral hepatitis in adults living in Daegu and Gyungbuk area (in Korean). Korean J Gastroenterol 2003;41:473-479.

12.

Lee JM, Lee JM, Yoo HS, Jang UK, Kim DJ, Kim YB, Kim HY, Park CK, Yoo JY: The prevalence of anti-HCV positivity in healthy Korean children (in Korean). Korean J Hepatol 1996;2:160-165.

13.

Ju YH, Shin HR, Oh JK, Kim DI, Lee DH, Kim BK, Kim JI, Jung KY: Seroepidemiologic study of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in young population in parts of Busan, Korea (in Korean). Korean J Prev Med 2004, in press.

14.

Shin HR, Kim JY, Ohno T, Cao K, Mizokami M, Risch H, Kim SR: Prevalence and risk factors of hepatitis C virus infection among Koreans in rural area of Korea. Hepatol Res 2000;17:185-196.

15.

Shin HR, Kim JY, Kim JI, Lee DH, Yoo KY, Lee DS, Franceschi S: Hepatitis B and C virus prevalence in a rural area of South Korea: The role of acupuncture. Br J Cancer 2002;87:314-318.

16.

Kim YS, Ahn YO, Kim DW: A case-control study on the risk factors of hepatitis C virus infection among Koreans. J Korean Med Sci 1996;11:38-43.

17.

Kim YS, Ahn YO, Lee HS: Risk factors for hepatitis C virus infection among Koreans according to the hepatitis C virus genotype. J Korean Med Sci 2002;17:187-192.

18.

Alter MJ: Epidemiology of hepatitis C. Hepatology 1997;26:S62-S65.

19.

Sladden TJ, Hickey AR, Dunn TM, Beard JR: Hepatitis C transmission on the north coast of New South Wales: Explaining the unexplained. Med J Aust 1997;166:290-293.

20.

Kemp R, Miller J, Lungley S, Baker M: Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations. N Z Med J 1998;111:50-53.

21.

Backmund M, Meyer K, Wachtler M, Eichenlaub D: Hepatitis C virus infection in injection drug users in Bavaria: Risk factors for seropositivity. Eur J Epidemiol 2003;18:563-568.

22.

Kim SY, Kim JK, Lee SH: Seropositivity of anti-HCV in intravenous drug abusers (in Korean). J Korean Acad Fam Med 1997;18:1508-1518.

23.

Kim YS, Ahn YO, Kim DW: Familial clustering of hepatitis B and C viruses in Korea. J Korean Med Sci 1994;9:444-449.

24.

Lee CG, Kim JS, Choi ES, Jeun MR, Chu SU, Hur C, Lee JK: Spousal transmission of hepatitis C virus (in Korean). Korean J Gastroenterol 1997;29:207-213.

25.

Lee DS, Sung YC, Whang YS: Distribution of HCV genotypes among blood donors, patients with chronic liver disease, hepatocellular carcinoma, and patients on maintenance hemodialysis in Korea. J Med Virol 1996;49:55-60.

26.

Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, Mukaide M, Williams R, Lau JY: New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997;35:201-207.

27.

Han CJ, Lee HS, Kim HS, Choe JH, Kim CY: Hepatitis C virus genotypes in Korea and their relationship to clinical outcome in type C chronic liver diseases (in Korean). Korean J Intern Med 1997;12:21-27.

28.

Park YS, Lee KO, Oh MJ, Chai YG: Distribution of genotypes in the 5' untranslated region of hepatitis C virus in Korea. J Med Microbiol 1998;47:643-647.

29.

Son HC, Yoon MS, Kim YJ, Kim IH, Kim YS: Type-specific antibody for hepatitis C virus detected by use of NS-4 peptide and hepatitis C virus genome in Korea. Rinsho Byori 2002;50:533-540.

30.

Kim CJ, Shin KS, Kim WY, Lim DS, Yoon SK, Park YM, Kim BS, Jang SK, Cho MJ: Genotype distribution and comparison of the putative envelope region of hepatitis C virus from Korean patients. J Med Virol 1995;46:380-386.

  Author Contacts

Hai-Rim Shin, MD
Research Institute for National Cancer & Evaluation, National Cancer Center
809 Madu-dong, Ilsan-gu, Goyang
Gyeonggi-do 411-769 (Korea)
Tel. +82 31 920 2050, Fax +82 31 920 2051, E-Mail hrshin@ncc.re.kr

  Article Information

Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 4, Number of References : 30

  Publication Details

Intervirology (International Journal of Basic and Medical Virology)

Vol. 49, No. 1-2, Year 2006 (Cover Date: 2006)

Journal Editor: Liebert, U.G. (Leipzig)
ISSN: 0300-5526 (print), 1423-0100 (Online)

For additional information: http://www.karger.com/int

  Drug Dosage / Copyright

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.